A bleak future for M’sia to get viable Covid-19 vaccine



[ad_1]

COMMENTARY | On August 2, a Bloomberg The news report stated that “rich countries have already locked up more than a billion doses of coronavirus vaccines, raising concerns that the rest of the world will be at the bottom of the queue in the global effort to defeat the pathogen.

“Although international groups and several nations promise to make vaccines affordable and accessible to all, doses are likely to struggle to meet demand in a world of approximately 7.8 billion people.”

The report then stated that “The possibility of richer countries monopolizing supply, a scenario that played out in the 2009 swine flu pandemic, has fueled concern among poor nations and health advocates.”

Although there are at least 40 Covid-19 vaccines undergoing phase 1 and phase 2 human clinical trials so far and seven candidate vaccines in final phase 3 clinical trials, I am not optimistic that a developing country like Malaysia can secure a vaccine. Covid-19 tested successfully. This is why.

1) Unlike some Asian countries, we do not have human vaccine manufacturing facilities that we can leverage with a vaccine developer interested in manufacturing their vaccine here under license.

It could have been a strategic mistake that when our BioValley Project began in 2003, we did not embark on a vaccine manufacturing program of this type.

2) In a world population of 7.8 billion people, even if a vaccine is found now, there is not enough …

[ad_2]